Seragon(美国)

Seragon Pharmaceuticals

SeragonPharmaceuticalswww.seragonpharm.comSeragonPharmaceuticals前身是Aragon的乳癌药物开发部门SeragonPharmaceuticals’orallyactiveselectiveestrogenreceptordegraders(SERDs)representapotentialnewtreatmentforpr ogressivemetastaticbreastcancerthatmaycircumventtheproblemofresistancetoanti-hormonaltherapies.SERDsareestrogenreceptorantagoniststhatalsoinduceaconformationalchangethatresultsinthedegradationofthereceptor.SeragonhasidentifiedmultipleSERDsthathavepharmacokineticprofilessufficienttodrivearobusttherapeuticresponseandresultindegradationofthereceptorandanti-tumoractivity.Thenovelprofileofthesepotent,orallybioavailable,nonsteroidalagentsmayresultingreaterefficacyandresponseratesinpatientswithhormone-refractorybreastcancercomparedtootherdrugsindevelopment.Seragon’smostadvancedleadsinducetumorregressionsinbothtamoxifensensitiveandtamoxifenresi